A radioactive prostate cancer therapy is a last lifeline for patients. Novartis can't make enough of it
Alfredo Najá Domingos’ prostate cancer was spreading. The malignant cells permeated his bones, kidney, lungs and liver, and in December, his oncologist told him there was no point in continuing chemotherapy treatment.
But there was a new treatment he could try: a targeted radiotherapy called Pluvicto — if he could get it in time. Both Moffitt Cancer Center and Mayo Clinic in Florida, not too far from Domingos and his family, said he would have to wait between three and a half and four months to get the treatment. His wife, Nora Flor, said she and her sister made calls to at least 30 centers across the US looking for the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
